Small-to-medium sized pharmaceutical and biotech companies are positioned to bring 50 percent of new drug molecules to market in the next decade. With escalating R&D costs and the long path to new medicine, these companies are forced to view outsourcing or contract services as an important part of their manufacturing strategy.
Biocon leverages its India cost-base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele. Biocon’s full set of customer manufacturing capabilities, include mammalian cell culture fermentation, microbial cell culture fermentation, synthetic chemistry. The facility has been inspected by various international regulators including the USFDA, EU Inspectors, BfArM and Anvisa.